Trials / Available
AvailableNCT05134922
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celcuity Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
Detailed description
The primary purpose of this study is to provide continuing access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gedatolisib | Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays. |
Timeline
- First posted
- 2021-11-26
- Last updated
- 2025-03-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05134922. Inclusion in this directory is not an endorsement.